Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19

Yıl: 2021 Cilt: 19 Sayı: 3 Sayfa Aralığı: 174 - 182 Metin Dili: İngilizce DOI: 10.21911/aai.676 İndeks Tarihi: 16-05-2022

Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19

Öz:
Objective: The clinical features of COVID-19 range from asymptomatic disease to severe pneumonia or even death. Therefore, many researchers have investigated the factors that could affect the severity of COVID-19. We aimed to assess the impact of aero-allergen sensitization and allergic diseases on the severity of COVID-19. Materials and Methods: We included 60 adult patients with symptomatic COVID-19 and allocated them into two groups equal in number as having severe and non-severe COVID-19. We evaluated the demographic features and allergic diseases in addition to clinical, laboratory and radiological findings of COVID-19. Skin prick tests (SPTs) with common aero-allergens, serum total IgE levels and blood eosinophil counts were evaluated 3 months after the patient’s recovery from COVID-19. Results: The mean age of the patients was 52 ± 11 years and 73.3% of the patients were male. There was no significant difference between the two groups in terms of age, gender, smoking habits, obesity and comorbidities. Although the frequency of sensitization to aero- allergens and the allergic diseases were similar, the history of allergic diseases in the family was higher in the severe group (p<0.001). The polysensitization in SPTs was associated with the presence of a cytokine storm during the infection (p=0.02). Total IgE levels and blood eosinophil counts were not significantly different between the two groups. Conclusion: The presence of atopy or allergic diseases does not seem to be related to the severity of COVID-19. However, polysensitization and a family history of allergic diseases are more prominent in those having a cytokine storm and severe COVID-19, respectively.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19): situation report. 2020 Access date: 1 January 2021. Available from: http://www.who.int.
  • 2. Azkur AK, Akdis M, Azkur D, Sokolowska M, Veen W, Brügggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75: 1564-81.
  • 3. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief- review of the risk factors for covid-19 severity. Rev Saude Publica 2020;54:60.
  • 4. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS- CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020;94: 91-5.
  • 5. Romagnani S. Immunologic influences on allergy and the TH1/ TH2 balance. J Allergy Clin Immunol 2004;113:395-400.
  • 6. Yang JM, Koh HY, Moon SY,Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol 2020;146:790- 8.
  • 7. Scala E, Abeni D, Tedeschi A, Manzotti G, Yang B, Borrelli P, et al. Atopic status protects from severe complications ofCOVID-19. Allergy 2021;76:899-902.
  • 8. Shi W, Gao Z, Ding Y, Zhu T, Zhang W, Xu Y. Clinical characteristics of COVID-19 patients combined with allergy. Allergy 2020;75: 2405-8.
  • 9. Wang L, Foer D, Bates DW, Boyce JA, Zhou L. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol 2020;146: 808-12.
  • 10. Pei-Fang Wei , editors. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl) 2020;133(9):1087-95.
  • 11. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, Luo Y, Gao C, Zeng W. Chest CT severity score: An imaging tool for assessing severe COVID-19. Radiol Cardiothorac Imaging 2020;2(2):e200047.
  • 12. Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis 2021;80:88-95.
  • 13. Migueres M, Davila I, Frati F, Azpeitia A, Jeanpetit Y, Barrand ML, et al. Types of sensitization to aeroallergens: Definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy 2014;4:16.
  • 14. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang TB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS- CoV-2 in Wuhan, China. Allergy 2020;75:1730-41.
  • 15. Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013;14:536- 42.
  • 16. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4.
  • 17. Chhapola Shukla S. ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19. Eur Arch Otorhinolaryngol 2020;278:2637-40.
  • 18. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M. The role of peripheral blood eosinophil counts in COVID-19 patients. Allergy 2021;76:471-82.
  • 19. Turner KJ. Epidemiology of atopic disease. In: Lessof MH, Lee TH, Kemeny CM, editors. Allergy: An international textbook. Williams & Wilkins; Baltimore: 1987.337-46.
  • 20. Prigione I, Morandi F, Tosca MA, Silvestri M, Pistoia V, Ciprandi G, Rossi GA. Interferon-gamma and IL-10 may protect from allergic polysensitization in children: Preliminary evidence. Allergy 2010;65(6):740-2.
  • 21. Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL. Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. J Allergy Clin Immunol 2017;140:909-20.
  • 22. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. A defective type 1 response to rhinovirus in atopic asthma. Thorax 2002;57:328-32.
  • 23. Campbell DE, Fryga AS, Bol S, Kemp AS. Intracellular interferon-gamma (IFN-gamma) production in normal children and children with atopic dermatitis. Clin Exp Immunol 1999;115:377-82.
APA Can A, Eyice Karabacak D, Tüzer C, Alibeyoglu A, Köse M, Demir S, Buyukozturk S, ÇOLAKOĞLU B, GELİNCİK A (2021). Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. , 174 - 182. 10.21911/aai.676
Chicago Can Ali,Eyice Karabacak Deniz,Tüzer Can,Alibeyoglu Alpay,Köse Murat,Demir Semra,Buyukozturk Suna,ÇOLAKOĞLU Bahauddin,GELİNCİK Asli Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. (2021): 174 - 182. 10.21911/aai.676
MLA Can Ali,Eyice Karabacak Deniz,Tüzer Can,Alibeyoglu Alpay,Köse Murat,Demir Semra,Buyukozturk Suna,ÇOLAKOĞLU Bahauddin,GELİNCİK Asli Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. , 2021, ss.174 - 182. 10.21911/aai.676
AMA Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. . 2021; 174 - 182. 10.21911/aai.676
Vancouver Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. . 2021; 174 - 182. 10.21911/aai.676
IEEE Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A "Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19." , ss.174 - 182, 2021. 10.21911/aai.676
ISNAD Can, Ali vd. "Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19". (2021), 174-182. https://doi.org/10.21911/aai.676
APA Can A, Eyice Karabacak D, Tüzer C, Alibeyoglu A, Köse M, Demir S, Buyukozturk S, ÇOLAKOĞLU B, GELİNCİK A (2021). Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. Astım Allerji İmmünoloji, 19(3), 174 - 182. 10.21911/aai.676
Chicago Can Ali,Eyice Karabacak Deniz,Tüzer Can,Alibeyoglu Alpay,Köse Murat,Demir Semra,Buyukozturk Suna,ÇOLAKOĞLU Bahauddin,GELİNCİK Asli Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. Astım Allerji İmmünoloji 19, no.3 (2021): 174 - 182. 10.21911/aai.676
MLA Can Ali,Eyice Karabacak Deniz,Tüzer Can,Alibeyoglu Alpay,Köse Murat,Demir Semra,Buyukozturk Suna,ÇOLAKOĞLU Bahauddin,GELİNCİK Asli Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. Astım Allerji İmmünoloji, vol.19, no.3, 2021, ss.174 - 182. 10.21911/aai.676
AMA Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. Astım Allerji İmmünoloji. 2021; 19(3): 174 - 182. 10.21911/aai.676
Vancouver Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19. Astım Allerji İmmünoloji. 2021; 19(3): 174 - 182. 10.21911/aai.676
IEEE Can A,Eyice Karabacak D,Tüzer C,Alibeyoglu A,Köse M,Demir S,Buyukozturk S,ÇOLAKOĞLU B,GELİNCİK A "Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19." Astım Allerji İmmünoloji, 19, ss.174 - 182, 2021. 10.21911/aai.676
ISNAD Can, Ali vd. "Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19". Astım Allerji İmmünoloji 19/3 (2021), 174-182. https://doi.org/10.21911/aai.676